This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.
Companion FOAs:
PAR-21-122 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
PAR-21-123 , R61/ R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II
Deadlines:
PAR-21-124 Expiration Date New Date June 21, 2024 per issuance of NOT-NS-23-095. (Original Expiration Date: February 21, 2024)
Direct costs cannot exceed $499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed $750,000.
